JP Morgan Private Wealth Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $113M | Sell |
3,406,550
-610,207
| -15% | -$21.6M | 0.32% | 79 |
|
|
2023
Q2 | $147M | Sell |
4,016,757
-1,238,624
| -24% | -$48.2M | 0.77% | 31 |
|
|
2023
Q1 | $214M | Sell |
5,255,381
-676,275
| -11% | -$29.2M | 0.45% | 53 |
|
|
2022
Q4 | $304M | Buy |
5,931,656
+29,350
| +0.5% | +$1.41M | 0.68% | 28 |
|
|
2022
Q3 | $258M | Sell |
5,902,306
-278,482
| -5% | -$13.5M | 0.68% | 25 |
|
|
2022
Q2 | $324M | Buy |
6,180,788
+119,374
| +2% | +$6.08M | 0.83% | 20 |
|
|
2022
Q1 | $314M | Buy |
6,061,414
+305,462
| +5% | +$15.8M | 0.68% | 24 |
|
|
2021
Q4 | $340M | Buy |
5,755,952
+257,228
| +5% | +$12.7M | 0.73% | 24 |
|
|
2021
Q3 | $237M | Buy |
5,498,724
+33,920
| +0.6% | +$1.5M | 0.58% | 34 |
|
|
2021
Q2 | $214M | Buy |
5,464,804
+587,172
| +12% | +$22.8M | 0.55% | 38 |
|
|
2021
Q1 | $177M | Sell |
4,877,632
-348,388
| -7% | -$12.4M | 0.57% | 39 |
|
|
2020
Q4 | $192M | Buy |
5,226,020
+382,102
| +8% | +$14M | 0.62% | 31 |
|
|
2020
Q3 | $169M | Buy |
4,843,918
+790,754
| +20% | +$27.7M | 0.66% | 31 |
|
|
2020
Q2 | $126M | Buy |
4,053,164
+112,539
| +3% | +$3.82M | 0.57% | 39 |
|
|
2020
Q1 | $122M | Buy |
3,940,625
+155,123
| +4% | +$5.29M | 0.69% | 29 |
|
|
2019
Q4 | $141M | Buy |
3,785,502
+133,877
| +4% | +$4.77M | 0.64% | 33 |
|
|
2019
Q3 | $124M | Buy |
3,651,625
+70,570
| +2% | +$2.57M | 0.65% | 35 |
|
|
2019
Q2 | $147M | Sell |
3,581,055
-83,859
| -2% | -$3.33M | 0.81% | 24 |
|
|
2019
Q1 | $148M | Buy |
3,664,914
+239,749
| +7% | +$9.6M | 0.77% | 26 |
|
|
2018
Q4 | $142M | Sell |
3,425,165
-31,380
| -0.9% | -$1.3M | 0.86% | 23 |
|
|
2018
Q3 | $145M | Sell |
3,456,545
-93,127
| -3% | -$3.59M | 0.71% | 24 |
|
|
2018
Q2 | $122M | Buy |
3,549,672
+268,312
| +8% | +$9.17M | 0.68% | 27 |
|
|
2018
Q1 | $110M | Sell |
3,281,360
-31,249
| -0.9% | -$1.07M | 0.75% | 27 |
|
|
2017
Q4 | $114M | Buy |
3,312,609
+75,763
| +2% | +$2.58M | 0.75% | 30 |
|
|
2017
Q3 | $110M | Buy |
3,236,846
+190,325
| +6% | +$6.12M | 0.79% | 23 |
|
|
2017
Q2 | $97.1M | Buy |
3,046,521
+14,177
| +0.5% | +$447K | 0.74% | 28 |
|
|
2017
Q1 | $98.4M | Buy |
3,032,344
+69,165
| +2% | +$2.18M | 0.76% | 24 |
|
|
2016
Q4 | $91.3M | Sell |
2,963,179
-52,412
| -2% | -$1.6M | 0.79% | 25 |
|
|
2016
Q3 | $96.9M | Buy |
3,015,591
+48,680
| +2% | +$1.63M | 0.9% | 19 |
|
|
2016
Q2 | $99.1M | Sell |
2,966,911
-20,539
| -0.7% | -$656K | 0.96% | 18 |
|
|
2016
Q1 | $84M | Buy |
2,987,450
+217,039
| +8% | +$6.2M | 0.8% | 27 |
|
|
2015
Q4 | $84.8M | Buy |
2,770,411
+180,772
| +7% | +$5.69M | 0.87% | 23 |
|
|
2015
Q3 | $77.2M | Buy |
2,589,639
+41,144
| +2% | +$1.32M | 0.97% | 21 |
|
|
2015
Q2 | $81.1M | Buy |
2,548,495
+56,091
| +2% | +$1.83M | 0.93% | 23 |
|
|
2015
Q1 | $82.3M | Buy |
2,492,404
+27,000
| +1% | +$858K | 0.94% | 23 |
|
|
2014
Q4 | $72.9M | Buy |
2,465,404
+22,521
| +0.9% | +$646K | 0.87% | 28 |
|
|
2014
Q3 | $68.5M | Buy |
2,442,883
+78,997
| +3% | +$2.22M | 0.88% | 25 |
|
|
2014
Q2 | $66.6M | Buy |
2,363,886
+66,768
| +3% | +$1.9M | 1.12% | 18 |
|
|
2014
Q1 | $70M | Buy |
2,297,118
+204,190
| +10% | +$6.09M | 1.28% | 12 |
|
|
2013
Q4 | $60.8M | Buy |
2,092,928
+118,518
| +6% | +$3.45M | 1.22% | 17 |
|
|
2013
Q3 | $53.8M | Buy |
1,974,410
+94,017
| +5% | +$2.56M | 1.22% | 13 |
|
|
2013
Q2 | $50M | Buy |
+1,880,393
| New | +$52M | 1.23% | 13 |
|
Other funds holding PFE
JP Morgan Private Wealth Advisors's PFE Position: Q3 2023 in Review
JP Morgan Private Wealth Advisors reduced its Pfizer (PFE) stake by 15% in Q3 2023, selling an estimated $21.6M and leaving 3,406,550 shares worth $113M. The position accounts for 0.32% of the portfolio, ranked #79.
JP Morgan Private Wealth Advisors first reported a position in PFE in Q2 2013 and has held it in 42 quarters since. The position peaked at $340M in Q4 2021. 2,928 funds tracked by Wall St. Rank hold PFE as of Q3 2023.
- JP Morgan Private Wealth Advisors held 3,406,550 shares of Pfizer worth $113M as of Q3 2023.
- JP Morgan Private Wealth Advisors sold 610,207 Pfizer shares in Q3 2023, an estimated $21.6M.
- Pfizer made up 0.32% of JP Morgan Private Wealth Advisors's portfolio in Q3 2023, its #79 holding.
- JP Morgan Private Wealth Advisors first reported a position in Pfizer in Q2 2013 and has held it in 42 quarters since.
- JP Morgan Private Wealth Advisors's Pfizer position peaked at $340M in Q4 2021.
- 2,928 funds tracked by Wall St. Rank held Pfizer as of Q3 2023.
Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.